CatalystMarker
Sign in
← board

IDXX

distress 1/10 · well-funded / low risk
$542.780%today-29% from 52w high
idexx.com11,000 employeesFounded 1983Westbrook, MEDiagnostics & Research
Revenue
$1141M
Liquidity
$201M
Runway
Shares 1y
-1%

Price & events

-21.5% over 6M
$526$612$698Jan 26Apr 26Jul 261.4Mrating: UBS: Neutral (2026-04-28)rating: Citigroup: Neutral (2026-04-15)rating: Stifel: Buy (2026-03-31)rating: Piper Sandler: Neutral (2026-02-09)rating: Barclays: Overweight (2026-02-05)rating: BTIG: Buy (2026-02-03)rating: UBS: Neutral (2026-02-03)
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-5.8%
1W
+0.3%
1M
-3.2%
3M
-21.8%
6M
+0.4%
1Y
+15.4%
2Y
-21.8%
5Y
+10.4%
All

Overview

Market Cap
$42.82B
Enterprise Value
$42.92B
Volume
11.76K
52 Week Range
$515 – $767
Total Shares
78.88M
Float Shares
78.58M
Short %
2.81%
% Held by Insiders
0.22%
% Held by Institutions
96.12%
RVOL
0.02x
Beta
1.55

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 78,882,997 · 0 offerings/1y · 0 PIPEs
  • 2025-11-138-Kmaterial_agreement
  • 2024-11-12SC 13G/Astrategic_stake
  • 2024-11-068-Kmaterial_agreement
  • 2024-11-04SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $708 (+31% upside) · 14 analysts
  • 2026-04-28UBSNeutral
  • 2026-04-15CitigroupNeutral
  • 2026-03-31StifelBuy
  • 2026-02-09Piper SandlerNeutral
  • 2026-02-05BarclaysOverweight
  • 2026-02-03BTIGBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.